Trial Profile

Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Molibresib (Primary)
Indications B-cell lymphoma; Carcinoma; Lymphoma; Pancreatic cancer; Solid tumours; T-cell lymphoma
Focus Adverse reactions

Most Recent Events

24 Sep 2020 Status changed from not yet recruiting to withdrawn prior to enrolment as protocol moved to disapproval.
26 Aug 2020 Planned initiation date changed from 14 Aug 2020 to 26 Feb 2021.
20 May 2020 Planned initiation date changed from 8 May 2020 to 14 Aug 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com